Fortis Healthcare: NTK Files Petition to Amend Claim Against Daiichi Sankyo
Fortis Healthcare Limited updated on litigation where NTK, a promoter shareholder, filed a petition to amend its claim against Daiichi Sankyo in the Tokyo District Court on February 12, 2026. The amendment focuses on preventing Daiichi Sankyo from obstructing acquisitions and corporate exercises through defamatory statements.
The litigation involves a substantial amount and potential obstruction of corporate actions. While this is an update on a procedural step, the underlying litigation could have a significant impact on the company's ownership structure and operations if resolved unfavorably.
The announcement is an update on ongoing litigation and does not contain new financial results or significant business changes that would positively or negatively impact the company's immediate outlook. It is a procedural update in a legal matter.
Fortis Healthcare Limited announced an update regarding the material litigation filed by Northern TK Venture Pte Ltd. (“NTK”), a promoter shareholder, against Daiichi Sankyo Company Limited before the Tokyo District Court in Japan. NTK, an indirect wholly-owned subsidiary of IHH Healthcare (the parent company), has submitted a petition to further amend its claim against Daiichi Sankyo. The Tokyo District Court delivered a copy of this Petition to Amend Claims to Daiichi Sankyo on February 17, 2026.
Previously, on November 14, 2023, and May 20, 2025, it was announced that NTK sought reliefs including INR109,299,359,054 (approximately ₹10,930 crore) for losses arising from tortious claims and defamation, along with accrued interest. NTK also sought an injunction to prevent Daiichi Sankyo from obstructing the open offers by making defamatory statements to SEBI and other third parties, and requested a statement to vindicate NTK’s reputation.
Following the completion of the open offers on November 10, 2025, the amended petition specifically aims to modify the injunctive claim. This amendment seeks to prevent Daiichi Sankyo from obstructing NTK's acquisition of shares and other investment and corporate exercises in Fortis and Malar Hospitals by making defamatory statements. Other reliefs sought by NTK remain unchanged. NTK reserves the right to further amend the amount of damages in the Petition to Amend Claims. Fortis Healthcare will provide further announcements on any material developments.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.